The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

NĚMEC Pavel GREŠLIKOVÁ Henrieta SMETANA Jan ZAORALOVÁ Romana KUPSKÁ Renata BERÁNKOVÁ Kristina FILKOVÁ Hana KRÁLOVÁ Dana KREJČÍ Jan POUR Luděk ZAHRADOVÁ Lenka SANDECKÁ Viera ADAM Zdeněk KUGLÍK Petr HÁJEK Roman

Year of publication 2008
Type Workshop
MU Faculty or unit

Faculty of Medicine

Citation
Description This study is aimed at comparison of ability to overcome the negative prognostic impact of the most common cytogenetic aberrations by treatment regimens based on Velcade or thalidomide. Both new drugs can overcome negative prognostic impact of all named chromosomal abnormalities except gain1q21. However, difference in PFS median between del 17p13 positive and negative patients is not relevant, because of presence of only 1 patient in negative group. The difference in PFS median in gain1q21 positive and negative patients treated by thalidomide based regimen suggests that thalidomide is not able to overcome negative prognostic impact of gain1q21 in contrary of treatment based on Velcade regimen, which probably may overcome poor prognosis of gain1q21. However this findings has to be confirmed on larger cohort of patients with longer follow-up.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.